Needham maintains Buy rating on Veradermics, $172 price target

Veradermics (NYSE: MANE), a biotech company, saw its shares rise 268% post-IPO. Its lead therapy, VDPHL01, showed positive phase 3 trial results, with 78.8% to 85% of patients reporting hair coverage improvements. The drug targets a $30B market for pattern hair loss. The company has $820M in cash and analysts' average price target is $170.

Veradermics' (MANE) oral hair-loss drug VDPHL01 met all goals in a Phase 3 trial, showing significant hair growth. Shares rose over 11% intraday. The drug is an extended-release oral minoxidil formulation, aiming to improve convenience and adherence. Veradermics plans to seek regulatory approval, but direct comparisons with generic minoxidil are pending.

Veradermics' stock rose 6% after its Phase III trial for male hair loss drug VDPHL01 met all endpoints, showing significant hair growth vs. placebo. The drug was well-tolerated, with 78.8% and 85.0% of patients reporting improvement in once-daily and twice-daily arms, respectively. Veradermics aims for FDA approval, potentially becoming the first oral pill for pattern hair loss in 30 years.

Veradermics (MANE) shares rose 10% after its oral hair-loss pill, VDPHL01, met all primary and secondary goals in a second Phase 3 trial. The pill increased hair count significantly compared to placebo with no serious cardiac events. The company expects 12-month safety data later this year. Veradermics has sufficient cash to potentially reach a launch, according to management.

Veradermics (NYSE:MANE) reported positive results from its Phase III trial for VDPHL01 in male pattern hair loss, meeting all endpoints. The trial showed strong growth with mild to moderate adverse events. The company plans to release extension data from Study 302 later this year and expects results from a female pattern hair loss study in 2027. Veradermics has $820 million in cash and is evaluating regulatory filing strategies.

Veradermics (MANE) stock rose 6.98% to $116.42 after positive Phase 3 trial results for its hair loss treatment VDPHL01, meeting all endpoints with statistical significance. The trial involved 536 males with mild-to-moderate hair loss, showing significant hair count increases compared to placebo. The company expects further data later this year and in 2027.